Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

BACKGROUND: Psilocybin has been suggested as a novel, rapid-acting treatment for depression. Two consecutive doses have been shown to markedly decrease symptom severity in an open-label setting or when compared to a waiting list group. To date, to our knowledge, no other trial compared a single, mod...

Descripción completa

Detalles Bibliográficos
Autores principales: von Rotz, Robin, Schindowski, Eva M., Jungwirth, Johannes, Schuldt, Anna, Rieser, Nathalie M., Zahoranszky, Katharina, Seifritz, Erich, Nowak, Albina, Nowak, Peter, Jäncke, Lutz, Preller, Katrin H., Vollenweider, Franz X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830149/
https://www.ncbi.nlm.nih.gov/pubmed/36636296
http://dx.doi.org/10.1016/j.eclinm.2022.101809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830149/
https://www.ncbi.nlm.nih.gov/pubmed/36636296
http://dx.doi.org/10.1016/j.eclinm.2022.101809

Ejemplares similares